{
  "docId": "019dd923-5de0-76bd-a169-83187257f35b",
  "docSlug": "5d146414b5cc38c9",
  "documentTitle": "Vaccines & Therapeutics Outlook Part I: Timelines and Success Factors",
  "authorId": "BCG",
  "authorName": "BCG",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 12,
  "pageCount": 34,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "timeline",
  "function": "compare_options",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a timeline framework to contrast traditional sequential development with a compressed, parallelized approach.",
  "elementsJson": [
    "timeline_visual",
    "callout_box"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5de0-76bd-a169-83187257f35b/12",
  "deckHref": "/decks/019dd923-5de0-76bd-a169-83187257f35b",
  "deckJsonHref": "/decks/019dd923-5de0-76bd-a169-83187257f35b.json",
  "deckAnchorHref": "/decks/019dd923-5de0-76bd-a169-83187257f35b#slide-12",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Current outlook points to a 12-18 month timeline from exploratory to start of phased approvals & assumes no significant R&D challenges",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-fefb-728e-ad97-86d84eb1bef4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "framework",
      "text": "Traditional vs Accelerated Timeline",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52524196-4ba9-4de9-9508-6973414ae43b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Development timeline: 12-18 month",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-fefb-728e-ad97-88108ca701e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.68,
        "y": 0.5
      },
      "kind": "paragraph",
      "text": "Current outlook points to a 12-18 month timeline from exploratory to start of phased approvals & assumes no significant R&D challenges. For early availability and access, manufacturing has been kick-started even before granting of EUAs.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca33f381-584e-44fd-b6ef-299f50992470",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Estimated best-case scenario, with stages developed simultaneously; 2. Phased approvals are sequential approvals for specific segments of population based on Phase 3 results; 3. Emergency Use Authorization; 4. There are no clear markers associated with long term protection against COVID-19; to support a surrogate endpoint, these markers would have to be defined; Source: FDA, CDC, Press search, BCG",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60c37a6b-4407-4e64-bed5-7100f1f35eda",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Vaccine development life cycle | Current development moving at turbo-charged pace; 12-18 month timeline unprecedented",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d3c2eae-b1a6-4026-b3be-6f8d40e4524d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "block",
      "matchId": "019dd95a-163f-72bd-8a09-155b1e7741c0",
      "evidence": "Top: traditional >5 yrs paradigm; bottom: accelerated 12-18 month pathway.",
      "confidence": 85
    },
    {
      "name": "Contrast Pairs",
      "slug": "contrast-pairs",
      "agent": "Storyteller",
      "layer": "loop",
      "matchId": "019dd95a-163f-72bd-8a09-180dd6454dac",
      "evidence": "Direct visual contrast between traditional and accelerated timelines.",
      "confidence": 82
    },
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "019dd95a-163f-72bd-8a09-13faad3da339",
      "evidence": "Title quotes the insight: 12-18 month timeline unprecedented.",
      "confidence": 88
    },
    {
      "name": "Annotation",
      "slug": "annotation",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "019dd95a-163f-72bd-8a09-1d2148dabc9c",
      "evidence": "Callouts label EUA, surrogate efficacy, interim Ph 1 data milestones.",
      "confidence": 75
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "05acd9fd-9678-4a51-a1a5-dcc9f71f5f67",
      "evidence": "Visual representation of project phases over a timeline",
      "confidence": 0.95
    },
    {
      "name": "Vaccine Development Lifecycle (Phases I-III + EUA)",
      "slug": null,
      "matchId": "019dd95a-1d21-7467-a460-e3c094539ad6",
      "evidence": "Stages labeled: Exploratory/Pre-clinical -> Phase 1/2/3 -> Approval -> Mfg scale-up.",
      "confidence": 90
    }
  ],
  "arcBeats": [
    {
      "to": 17,
      "from": 9,
      "beatId": "019dd95a-0702-74a3-87e3-afd1671a9591",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Vaccines/therapeutics as path; timelines, fast movers, success factors",
      "position": 3,
      "confidence": 78,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 14,
      "from": 4,
      "beatId": "019dd95a-0702-74a3-87e3-b9ab3fe072a9",
      "arcName": "The Triple Take",
      "arcSlug": "triple-take",
      "beatName": "The Facts (What)",
      "beatSlug": "triple-take-the-facts-what",
      "evidence": "Snapshot, epidemic curves, vaccine pipeline, timelines",
      "position": 1,
      "confidence": 65,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 9,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "019dd95a-088c-724c-b30f-be0320e082a4",
      "evidence": "p11-12 frame unprecedented response and 12-18 month window; p13-14 detail fast movers and Q2 2021 distribution.",
      "position": 3,
      "objective": "Establish unprecedented vaccine response and timeline opportunity",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 75,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}